Abstract: A first device may receive, from a second device associated with an emergency motor vehicle (EMV), EMV-tracking information and a communication that the EMV is in emergency response mode and may determine, based on the EMV-tracking information, that the EMV is approaching an intersection. The first device may receive, from a third device associated with a user vehicle, user-tracking information. The first device may determine, based on the user-tracking information, that the user vehicle is approaching the intersection. The first device may determine, based on the EMV-tracking information and the user-tracking information, whether the EMV is predicted to collide with the user vehicle. The first device may provide, to the second device and based on the determination of whether the EMV is predicted to collide with the user vehicle, a first notification including information regarding safety of the EMV proceeding through the intersection.

Abstract: A first device may receive, from a second device associated with an emergency motor vehicle (EMV), EMV-tracking information and a communication that the EMV is in emergency response mode and may determine, based on the EMV-tracking information, that the EMV is approaching an intersection. The first device may receive, from a third device associated with a user vehicle, user-tracking information. The first device may determine, based on the user-tracking information, that the user vehicle is approaching the intersection. The first device may determine, based on the EMV-tracking information and the user-tracking information, whether the EMV is predicted to collide with the user vehicle. The first device may provide, to the second device and based on the determination of whether the EMV is predicted to collide with the user vehicle, a first notification including information regarding safety of the EMV proceeding through the intersection.

Abstract: A first device may receive, from a second device associated with an emergency motor vehicle (EMV), EMV-tracking information and a communication that the EMV is in emergency response mode and may determine, based on the EMV-tracking information, that the EMV is approaching an intersection. The first device may receive, from a third device associated with a user vehicle, user-tracking information. The first device may determine, based on the user-tracking information, that the user vehicle is approaching the intersection. The first device may determine, based on the EMV-tracking information and the user-tracking information, whether the EMV is predicted to collide with the user vehicle. The first device may provide, to the second device and based on the determination of whether the EMV is predicted to collide with the user vehicle, a first notification including information regarding safety of the EMV proceeding through the intersection.

Abstract: A travel management platform can determine a refueling event for a vehicle, can identify a plurality of refueling stations based on the refueling event, can provide, to the plurality of refueling stations, one or more parameters for the refueling event, can receive respective offers for the refueling event, can select an offer for the refueling event from the respective offers for the refueling event, and can perform various actions, such as transmitting an instruction to autonomously navigate the vehicle to a refueling station associated with the offer for the refueling event, transmitting an instruction to display a notification associated with the offer for refueling event, transmitting information associated with the offer for refueling event, transmitting information associated with the refueling station associated with the offer for the refueling event, and/or the like.

Abstract: A first device may receive, from a second device associated with an emergency motor vehicle (EMV), EMV-tracking information and a communication that the EMV is in emergency response mode and may determine, based on the EMV-tracking information, that the EMV is approaching an intersection. The first device may receive, from a third device associated with a user vehicle, user-tracking information. The first device may determine, based on the user-tracking information, that the user vehicle is approaching the intersection. The first device may determine, based on the EMV-tracking information and the user-tracking information, whether the EMV is predicted to collide with the user vehicle. The first device may provide, to the second device and based on the determination of whether the EMV is predicted to collide with the user vehicle, a first notification including information regarding safety of the EMV proceeding through the intersection.

Abstract: A first device may receive, from a second device associated with an emergency motor vehicle (EMV), EMV-tracking information and a communication that the EMV is in emergency response mode and may determine, based on the EMV-tracking information, that the EMV is approaching an intersection. The first device may receive, from a third device associated with a user vehicle, user-tracking information. The first device may determine, based on the user-tracking information, that the user vehicle is approaching the intersection. The first device may determine, based on the EMV-tracking information and the user-tracking information, whether the EMV is predicted to collide with the user vehicle. The first device may provide, to the second device and based on the determination of whether the EMV is predicted to collide with the user vehicle, a first notification including information regarding safety of the EMV proceeding through the intersection.

Abstract: A travel management platform can determine a refueling event for a vehicle, can identify a plurality of refueling stations based on the refueling event, can provide, to the plurality of refueling stations, one or more parameters for the refueling event, can receive respective offers for the refueling event, can select an offer for the refueling event from the respective offers for the refueling event, and can perform various actions, such as transmitting an instruction to autonomously navigate the vehicle to a refueling station associated with the offer for the refueling event, transmitting an instruction to display a notification associated with the offer for refueling event, transmitting information associated with the offer for refueling event, transmitting information associated with the refueling station associated with the offer for the refueling event, and/or the like.

Abstract: Currently there is no conventional tool kit/method available to determine the most appropriate drug delivery technology for a drug molecule. Instead, different drug delivery options are investigated through actual experimentation, and the most appropriate drug delivery technology is selected based on trial and error. Embodiments of the current disclosure provide an innovative, unique, versatile, all-inclusive tool kit/method for one or more appropriate delivery technologies to be recommended by a drug-technology company providing those technologies to a customer for a given drug molecule based on the characteristics of a the drug molecule provided as input.

Abstract: Compositions and methods disclosed herein capitalize on the discovery that rejection of a tissue graft can be inhibited using a CD40:CD154 binding interrupter, either alone or in combination with another immunomodulator or immunosuppressor. An advantageous, synergistic combination includes a CD40:CD154 binding interrupter and a CD28 signaling interrupter. An exemplary CD40:CD154 binding interrupter is an anti-CD154 monoclonal antibody, such as an antibody having the antigen-specific binding characteristics of the 5c8 monoclonal antibody. An exemplary CD28 signaling interrupter is a CTLA4-Ig fusion protein. The disclosed compositions and methods unexpectedly can be used to prolong survival of grafted tissue in a recipient host, to reverse acute graft rejection, and to attenuate immunological consequences of the failure of grafted tissue.

Abstract: A filtration assembly operable in connection with a crystal form screening workstation that provides for automated crystal form screening is disclosed. The assembly includes first and second valves, with each valve having an internal passage and first, second and third ports. A filter line is interposed between the first and second valves in fluid communication with the second port of the first valve and the second port of the second valve. A filter medium is in disposed in or at the end of the filter line and adapted to filter a drug-containing suspension flowing through the filter line. The filter medium is operable to filter fluids under both positive and negative pressure conditions.

Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).

Abstract: The invention relates to methods for identifying agents, which bind to and/or modulate exopeptidases or endopeptidases, preferably human soluble secreted endopeptidase (SEP), oxytocinase, neutral endopeptidase (NEP), or non-human SEP, preferably comprising contacting said agents with a polypeptide comprising: SEQ ID NO: 2, an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 5; or a polypeptide encoded by the cDNA of NCIMB 41110, and determining whether binding and/or modulation occurs. Preferably, said method is carried out in the presence of a substrate peptide labelled with at least one fluorescent donor dye and at least one fluorescence acceptor dye, with the method used to detect said agents being a competitive binding Fluorescence Resonance Energy Transfer (FRET) assay.

Abstract: Polynucleotide and polypeptide sequences are described. The polypeptide sequences comprise one or more of: (a) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence in SEQ ID NO: 1 or SEQ ID NO: 5 and variants, fragments, homologues, analogues and derivatives thereof; (b) a polypeptide of SEQ ID NO: 2 and variants, fragments, homologues, analogues and derivatives thereof; (c) a polypeptide encoded by the cDNA of NCIMB 41110 and variants, fragments, homologues, analogues and derivatives thereof; or (d) a polypeptide which has at least 78% identity to (i) the polypeptide encoded by the polynucleotide of SEQ ID NO: 1 or SEQ ID NO: 5, (ii) the polypeptide of SEQ ID NO: 2, or (iii) the polypeptide encoded by the cDNA of NCIMB 41110. Such polypeptide sequences are, inter alia, useful in the prophylaxis and/or treatment of sexual dysfunction, in particular male erectile dysfunction (MED) or female sexual dysfunction (FSD), preferably female sexual arousal disorder (FSAD).